We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-13.19%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.78B
AUM Growth
+$18.3M
Cap. Flow
+$336M
Cap. Flow %
12.09%
Top 10 Hldgs %
42.27%
Holding
179
New
61
Increased
32
Reduced
13
Closed
19

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$37.6M
2
UNH icon
UnitedHealth
UNH
+$37.4M
3
UTHR icon
United Therapeutics
UTHR
+$29.3M
4
MRK icon
Merck
MRK
+$27.6M
5
A icon
Agilent Technologies
A
+$24.1M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$27.7M
2
CELG
Celgene Corp
CELG
+$26.8M
3
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$26.5M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$23.7M
5
ACOR
Acorda Therapeutics
ACOR
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 84.85%
2 Miscellaneous 10.25%
3 Real Estate 3.57%
4 Financials 1.31%
5 Technology 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HR
101
DELISTED
Healthcare Realty Trust Incorporated
HR
$4.65M 0.17%
+187,224
New +$4.46M
FOMX
102
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$4.5M 0.16%
613,577
+199,777
+48% +$2.04M
CLLS
103
Cellectis
CLLS
$162M
$4.17M 0.15%
158,382
+118,382
+296% +$3.96M
SAGE
104
DELISTED
Sage Therapeutics
SAGE
$4.14M 0.15%
97,800
+82,800
+552% +$5.1M
ORKA
105
Oruka Therapeutics
ORKA
$6.1B
$4.03M 0.14%
+3,756
New +$5.72M
RCKT icon
106
Rocket Pharmaceuticals
RCKT
$374M
$4M 0.14%
+106,250
New +$4.88M
LXRX icon
107
CALL
Lexicon Pharmaceuticals
LXRX
$894M
$3.8M 0.14%
+353,900
New +$3.87M
LXRX icon
108
Lexicon Pharmaceuticals
LXRX
$894M
$3.8M 0.14%
+353,900
New +$3.87M
GWPH
109
CALL
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$3.78M 0.14%
+41,400
New +$4.6M
ACHN
110
DELISTED
Achillion Pharmaceuticals
ACHN
$3.78M 0.14%
547,300
– –
ASRT
111
DELISTED
Assertio
ASRT
$3.77M 0.14%
+3,333
New +$5.69M
BMRN icon
112
CALL
BioMarin Pharmaceuticals
BMRN
$12.5B
$3.74M 0.13%
+35,500
New +$4.74M
CLDX icon
113
Celldex Therapeutics
CLDX
$3.02B
$3.57M 0.13%
+22,560
New +$6.39M
SAGE
114
CALL
DELISTED
Sage Therapeutics
SAGE
$3.5M 0.13%
+82,800
New +$5.1M
PBYI icon
115
CALL
Puma Biotechnology
PBYI
$477M
$3.42M 0.12%
+45,400
New +$4.29M
ADAP
116
DELISTED
Adaptimmune Therapeutics
ADAP
$3.38M 0.12%
281,934
+254,434
+925% +$3.59M
KPTI icon
117
CALL
Karyopharm Therapeutics
KPTI
$34.9M
$3.34M 0.12%
+21,127
New +$5.65M
EPZM
118
DELISTED
Epizyme, Inc
EPZM
$3.3M 0.12%
256,700
+56,700
+28% +$1.14M
WMGI
119
DELISTED
Wright Medical Group Inc
WMGI
$3.28M 0.12%
156,100
– –
HZNP
120
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.23M 0.12%
+162,900
New +$5.15M
HZNP
121
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.23M 0.12%
+162,900
New +$5.15M
CRDF icon
122
Cardiff Oncology
CRDF
$104M
$3.13M 0.11%
+7,639
New +$4M
FWP
123
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$3.12M 0.11%
+18,921
New +$3.98M
PRGO icon
124
Perrigo
PRGO
$1.88B
$2.97M 0.11%
+18,900
New +$3.47M
ALXN
125
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$2.85M 0.1%
+18,200
New +$3.32M
3 4
5
6 7

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, Tekla Capital Management held 179 positions worth $2.78B, up 0.66% from $2.76B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tekla Capital Management deployed $336M of net new capital in Q3 2015, opening 61 new positions and adding to 32 existing holdings. Its largest new stake was UnitedHealth: 312,600 shares worth $36.3M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 87% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Amgen, an estimated $27.7M trimmed.

  • Tekla Capital Management's largest Q3 2015 buy was UnitedHealth: 312,600 shares worth $36.3M.
  • Tekla Capital Management added most to Biogen in Q3 2015, an estimated $37.6M increase.
  • Tekla Capital Management's biggest Q3 2015 reduction was Amgen, cutting an estimated $27.7M.
  • Tekla Capital Management fully exited CATAMARAN CORP COM STK (CDA) in Q3 2015, selling an estimated $26.5M.
  • Tekla Capital Management's ten largest holdings make up 42% of its $2.78B portfolio in Q3 2015.
  • Tekla Capital Management opened 61 new positions and closed 19 in Q3 2015.
  • Tekla Capital Management's portfolio value rose 0.66% quarter-over-quarter to $2.78B.

Based on Tekla Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.